Why are mineralocorticoid receptor antagonists cardioprotective?
about
Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptorTwo-pore domain potassium channels in the adrenal cortex.Invalidation of TASK1 potassium channels disrupts adrenal gland zonation and mineralocorticoid homeostasisAldosterone predicts major adverse cardiovascular events in patients with acute myocardial infarction.Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy.Modulation of the cardiac sodium/bicarbonate cotransporter by the renin angiotensin aldosterone system: pathophysiological consequences.Therapeutic inhibition of the renin angiotensin aldosterone system.Non-genomic effect of glucocorticoids on cardiovascular system.Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice.Hsd11b2 haploinsufficiency in mice causes salt sensitivity of blood pressure.Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system.Mineralocorticoid receptor activation is crucial in the signalling pathway leading to the Anrep effect.Comparison of the effects of intrapericardial and intravenous aldosterone infusions on left ventricular fibrosis in rats.Genomic and rapid effects of aldosterone: what we know and do not know thus far.Detection of 11 beta-hydroxysteroid dehydrogenase type 1, the glucocorticoid and mineralocorticoid receptor in various adipose tissue depots of dairy cows supplemented with conjugated linoleic acids.
P2860
Q35071304-50BCCFE0-8945-4D61-8082-0AB753B81804Q35597757-916D1061-FF05-478A-848E-DF0DC2620D09Q36391968-8C98B279-CD33-4927-9703-12EC81E87EECQ36800757-A970D3CD-8485-4A78-88EC-685F76E0B4BCQ37000764-968AF0A1-D11D-41BC-AFC6-CD9CF4741218Q37167020-9136050C-ABFF-4BEC-B1BF-AC53460122E4Q37488893-ADB7F39C-2885-4A79-916A-B2329C32DAACQ37489951-BF1AE22E-1109-46AA-8A8C-FE1210281CFFQ38045751-A4430823-FA42-4B31-B135-F7115777D715Q39230094-2D0F5619-7C5B-4A60-B039-D265EE5B47C3Q40129518-E396778D-25E7-4DE0-A627-3CA6D93ED52CQ40151299-E8392B6B-DFBA-4439-B6F2-3C5D9A830CA3Q42089235-FD2B2866-6546-4096-9E25-7BF82C3BD6A8Q42499067-B7D8357C-FD0B-4FB0-B423-5C081E0C1100Q45231099-2478D97D-29F3-4D9D-85E6-A84A803BA18BQ51273122-B9FFF7E9-8CBB-4183-940C-97FCB3410CF3Q53007901-AD2C9F95-9349-4AE3-92A2-97C6C55FDDCD
P2860
Why are mineralocorticoid receptor antagonists cardioprotective?
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Why are mineralocorticoid receptor antagonists cardioprotective?
@ast
Why are mineralocorticoid receptor antagonists cardioprotective?
@en
type
label
Why are mineralocorticoid receptor antagonists cardioprotective?
@ast
Why are mineralocorticoid receptor antagonists cardioprotective?
@en
prefLabel
Why are mineralocorticoid receptor antagonists cardioprotective?
@ast
Why are mineralocorticoid receptor antagonists cardioprotective?
@en
P2860
P921
P1476
Why are mineralocorticoid receptor antagonists cardioprotective?
@en
P2093
A H Jan Danser
Wenxia Chai
P2860
P2888
P304
P356
10.1007/S00210-006-0107-9
P577
2006-10-31T00:00:00Z
2006-12-01T00:00:00Z